Works matching IS 10837159 AND DT 2022 AND VI 27 AND IP 2
Results: 23
Blurring the Lines of Design: Prospective Observational Cohorts and Pragmatic Clinical Trials Characterizing Treatment Effects in Routine Cancer Care.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 79, doi. 10.1093/oncolo/oyab071
- By:
- Publication type:
- Article
First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 125, doi. 10.1093/oncolo/oyab056
- By:
- Publication type:
- Article
Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 82, doi. 10.1093/oncolo/oyab052
- By:
- Publication type:
- Article
Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 135, doi. 10.1093/oncolo/oyab049
- By:
- Publication type:
- Article
Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. e199, doi. 10.1093/oncolo/oyab047
- By:
- Publication type:
- Article
Rational Second-Generation Antiandrogen Use in Prostate Cancer.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 110, doi. 10.1093/oncolo/oyab045
- By:
- Publication type:
- Article
Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. e116, doi. 10.1093/oncolo/oyab044
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. e126, doi. 10.1093/oncolo/oyab043
- By:
- Publication type:
- Article
Outcomes of Breast Cancer Patients Treated with Chemotherapy, Biologic Therapy, Endocrine Therapy, or Active Surveillance During the COVID-19 Pandemic.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 89, doi. 10.1093/oncolo/oyab042
- By:
- Publication type:
- Article
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 149, doi. 10.1093/oncolo/oyab040
- By:
- Publication type:
- Article
Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. e203, doi. 10.1093/oncolo/oyab037
- By:
- Publication type:
- Article
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. e194, doi. 10.1093/oncolo/oyab036
- By:
- Publication type:
- Article
Cardiotoxicity from Capecitabine Chemotherapy: Prospective Study of Incidence at Rest and During Physical Exercise.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. e158, doi. 10.1093/oncolo/oyab035
- By:
- Publication type:
- Article
Age-related Differences in Recall of Information and Handling of Chemotherapy-related Side Effects in Cancer Patients: The ReCap Study.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. e185, doi. 10.1093/oncolo/oyab034
- By:
- Publication type:
- Article
Prospective Comparison of Geriatric Assessment and Provider's Assessment of Older Adults With Metastatic Breast Cancer in the Community.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. e133, doi. 10.1093/oncolo/oyab032
- By:
- Publication type:
- Article
Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 144, doi. 10.1093/oncolo/oyab031
- By:
- Publication type:
- Article
Factors Associated with Time to Progression and Overall Survival in Patients with De Novo Metastatic Breast Cancer: A Colombian Cohort.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. e142, doi. 10.1093/oncolo/oyab023
- By:
- Publication type:
- Article
Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 104, doi. 10.1093/oncolo/oyab028
- By:
- Publication type:
- Article
Prevalence of BRCA1 and BRCA2 Germline Mutations in Patients of African Descent with Early-Onset and Familial Colombian Breast Cancer.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. e151, doi. 10.1093/oncolo/oyab026
- By:
- Publication type:
- Article
Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 97, doi. 10.1093/oncolo/oyab024
- By:
- Publication type:
- Article
Smoking Is Related to Worse Cancer-related Symptom Burden.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. e176, doi. 10.1093/oncolo/oyab029
- By:
- Publication type:
- Article
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 87, doi. 10.1002/onco.13951
- By:
- Publication type:
- Article
Perceptions of Hope Among Bereaved Caregivers of Cancer Patients Who Received Early Palliative Care: A Content and Lexicographic Analysis.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. e168, doi. 10.1093/oncolo/oyab027
- By:
- Publication type:
- Article